1. Home
  2. CMC vs CRSP Comparison

CMC vs CRSP Comparison

Compare CMC & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Commercial Metals Company

CMC

Commercial Metals Company

HOLD

Current Price

$80.33

Market Cap

6.4B

Sector

Industrials

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$45.74

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMC
CRSP
Founded
1915
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
5.1B
IPO Year
1987
2016

Fundamental Metrics

Financial Performance
Metric
CMC
CRSP
Price
$80.33
$45.74
Analyst Decision
Buy
Buy
Analyst Count
10
20
Target Price
$71.10
$71.95
AVG Volume (30 Days)
1.4M
1.8M
Earning Date
03-19-2026
02-11-2026
Dividend Yield
0.87%
N/A
EPS Growth
235.90
N/A
EPS
3.85
N/A
Revenue
$8,009,185,000.00
$38,337,000.00
Revenue This Year
$17.16
N/A
Revenue Next Year
$6.68
$1,376.73
P/E Ratio
$21.48
N/A
Revenue Growth
2.25
N/A
52 Week Low
$37.92
$30.04
52 Week High
$84.12
$78.48

Technical Indicators

Market Signals
Indicator
CMC
CRSP
Relative Strength Index (RSI) 62.85 33.36
Support Level $74.66 $49.10
Resistance Level $84.12 $53.00
Average True Range (ATR) 2.55 3.16
MACD 0.28 -0.78
Stochastic Oscillator 65.92 0.14

Price Performance

Historical Comparison
CMC
CRSP

About CMC Commercial Metals Company

Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: